Evidence map›Paper›PMID 28039552›Full record

ArticleEuropean archives of psychiatry and clinical neuroscience2017

Cerebrospinal fluid microglia and neurodegenerative markers in twins concordant and discordant for psychotic disorders.

Viktoria Johansson, Joel Jakobsson, Rebecca G Fortgang, Henrik Zetterberg, Kaj Blennow, Tyrone D Cannon, Christina M Hultman, Lennart Wetterberg, Mikael Landén

Open access · hybridAbstract readTwin Study
In one paragraph

Article in European archives of psychiatry and clinical neuroscience, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Abnormalities in the brain-immune system in psychotic disorders: from pathogenesis to prevention.European archives of psychiatry and clinical neuroscience · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Viktoria JohanssonDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. viktoria.johansson@ki.se.ORCID http://orcid.org/0000-0003-3775-7245
Joel JakobssonInstitute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden.
Rebecca G FortgangDepartment of Psychology, Yale University, New Haven, USA.
Henrik ZetterbergInstitute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden.
Kaj BlennowInstitute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden.
Tyrone D CannonDepartment of Psychology, Yale University, New Haven, USA.
Christina M HultmanDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Lennart WetterbergDepartment of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Mikael LandénDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Karolinska Institutet · SEUniversity of Gothenburg · SEYale University · USNational Hospital for Neurology and Neurosurgery · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Schizophrenia and bipolar disorder are debilitating psychiatric disorders with partially shared symptomatology including psychotic symptoms and cognitive impairment. Aberrant levels of microglia and neurodegenerative cerebrospinal fluid (CSF) markers have previously been found in schizophrenia and bipolar disorder. We aimed to analyze familial and environmental influences on these CSF markers and their relation to psychiatric symptoms and cognitive ability. CSF was collected from 17 complete twin pairs, nine monozygotic and eight dizygotic, and from one twin sibling. Two pairs were concordant for schizophrenia, and 11 pairs discordant for schizophrenia, schizoaffective disorder or bipolar disorder, and four pairs were not affected by psychotic disorders. Markers of microglia activation [monocyte chemoattractant protein-1 (MCP-1), chitinase 3-like protein 1 (YKL-40), and soluble cluster of differentiation 14 (sCD14)], markers of β-amyloid metabolism (AβX-38, AβX-40, AβX-42 and Aβ1-42), soluble amyloid precursor proteins (sAPP-α and sAPP-β), total tau (T-tau), phosphorylated tau (P-tau), and CSF/serum albumin ratio were measured in CSF using immunoassays. Heritability of the CSF markers was estimated, and associations to psychiatric and cognitive measurements were analyzed. Heritability estimates of the microglia markers were moderate, whereas several neurodegenerative markers showed high heritability. In contrast, AβX-42, Aβ1-42, P-tau and CSF/serum albumin ratio were influenced by dominant genetic variation. Higher sCD14 levels were found in twins with schizophrenia or bipolar disorder compared to their not affected co-twins, and higher sCD14-levels were associated with psychotic symptoms. The study provides support for a significant role of sCD14 in psychotic disorders and a possible role of microglia activation in psychosis.

Indexed as

Diseases in TwinsAdultAmyloid beta-PeptidesBiomarkersChemokine CCL2Chitinase-3-Like Protein 1FemaleGenetic Predisposition to DiseaseHumansLipopolysaccharide ReceptorsMaleMiddle AgedPsychometricsPsychotic DisordersStatistics as TopicTwins, DizygoticAmyloid beta-PeptidesBiomarkersCCL2 protein, humanChemokine CCL2CHI3L1 protein, humanChitinase-3-Like Protein 1Lipopolysaccharide ReceptorsBiomarkerBipolar disorderCerebrospinal fluidNeuroinflammationSchizophreniaTwin study

Identifiers

PMID28039552
PMCPMC5509775
OpenAlexW2561806107

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.